GlaxoSmithKline plc with ticker (LON:GSK) now has a potential upside of 7.0% according to Berenberg Bank.
Berenberg Bank set a target price of 1,850 GBX for the company, which when compared to the GlaxoSmithKline plc share price of 1,721 GBX at opening today (12/05/2022) indicates a potential upside of 7.0%. Trading has ranged between 1,326 (52 week low) and 1,817 (52 week high) with an average of 10,107,689 shares exchanging hands daily. The market capitalisation at the time of writing is £86,946,137,967.
GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
GlaxoSmithKline plc 7.0% potential upside indicated by Berenberg Bank
[shareaholic app="share_buttons" id_name="post_below_content"]
- Written by: Charlotte Edwards
Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
GSK reports success in phase III trial of Zejula and Jemperli for advanced ovarian cancer, achieving significant progression-free survival improvement.
GSK's Jemperli receives FDA Breakthrough Therapy Designation for treating locally advanced dMMR/MSI-H rectal cancer, expediting crucial development.
GSK announces FDA review of Nucala for COPD treatment following successful MATINEE study data, aiming to be the first approved monthly biologic.
GSK's Arexvy vaccine receives approval in Japan to protect adults aged 50-59 at increased risk from severe RSV infection, expanding its coverage.
